Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 4, 2011, Pages 408-414

  Clemens, Evan C ^a   Chan, Jeannie D ^a   Lynch, John B ^b   Dellit, Timothy H ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Methicillin resistant Staphylococcus aureus; Minimum inhibitory concentration; Vancomycin

Indexed keywords

CLINDAMYCIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BLOOD CULTURE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREND STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; COHORT STUDIES; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 82555172160     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.08.002     Document Type: Article

References (34)

1. Beeston C., Gupta R., Chadwick P., Young R. Methicillin-resistant Staphylococcus aureus bacteraemia and mortality in a teaching hospital. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28:585-590.
2. Bellomo R., Ronco C., Kellum J., Mehta R., Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Cirt. Care 2004, 8:R204-R212. ADQI work group.
3. Bennett J., Murray C., Holmes R., Patterson J., Jorgensen J. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2008, 60:437-440.
4. Chan J.D., Pham T., Wong J., et al. Clinical outcomes of linezolid vs. vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J. Intensive Care Med. 2011, Available at, [Epub ahead of print]. http://jic.sagepub.com/content/early/2010/12/04/0885066610392893.
5. Cosgrove S., Sakoulas G., Perencevich E., Schwaber M., Karchmer A., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta analysis. Clin. Infect. Dis. 2003, 36:53-59.
6. Haque N.Z., Zuniga L.C., Peyrani P., et al. Relationship of vancomycin minimum inhibtory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-acquired, or health-care associated pneumonia. Chest 2010, 138:1356-1362.
7. Hartzell J., Neff R., Ake J., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 2009, 48:1724-1728.
8. Hazlewood K., Brouse S., Pitcher W., Hall R. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?. Am. J. Med. 2010, 123:182.e1-182.e7.
9. Hidayat L., Hsu D., Quist R., Shriner K., Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 2006, 166:2138-2144.
10. Horne K., Howden B., Grabsch E., et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob. Agents Chemother. 2009, 53:3447-3452.
11. Howden B., Davies J., Johnson P., Stinear T., Grayson M. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 2010, 23:99-139.
12. Hsu D., Hidayat L., Quist R., et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 2008, 32:378-385.
13. Jeffres M., Isakow W., Doherty J., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130:947-955.
14. Jevitt L., Smith A., Williams P., Raney J., McGowan J., Tenover F. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 2003, 9:389-393.
15. Kellum J., Bellomo R., Rono C. Definition and classification of acute kidney injury. Nephron. Clin. Pract. 2008, 109:c182-c187.
16. Kim S.H., Kim K.K., Kim H.B., et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 2008, 52:192-197.
17. Lalueza A., Chaves F., San Juan R., Daskalaki M., Otero J., Aguado J. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia?. J. Infect. Dis. 2010, 201:311-312. (author reply 312-313).
18. Lodise T., Graves J., Evans A., et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 2008, 52:3315-3320.
19. Lodise T., Patel N., Lomaestro B., Rodvold K., Drusano G. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 2009, 49:507-514.
20. Moise P., Smyth D., El-Fawal N., et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteremia. J. Antimicrob. Chemother. 2008, 61:85-90.
21. Moise P., North D., Steenbergen J., Sakoulas G. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 2009, 9:617-624.
22. Moise-Broder P., Sakoulas G., Eliopoulos G., Schentag J., Forrest A., Mollering R.J. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 2004, 38:1700-1705.
23. Musta A., Riederer K., Shemes S., et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 2009, 47:1640-1644.
24. Patel J., Jevitt L.A., Hageman J., McDonald L.C., Tenover F. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin. Infect. Dis. 2006, 42:1652-1653.
25. Patel N., Lubanski P., Ferro S., et al. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2009, 53:5141-5144.
26. Peleg A., Monga D., Pillai S., Mylonakis E., Moellering R.J., Eliopoulos G. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J. Infect. Dis. 2009, 199:532-536.
27. Price J., Atkinson S., Llewelyn M., Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin. Infect. Dis. 2009, 48:997-998.
28. Rybak M., Lomaestro B., Rotschafer J., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 2009, 66:82-98.
29. Sader H., Fey P., Limaye A., et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 2009, 53:4127-4132.
30. Sakoulas G., Moise-Broder P., Schentag J., Forrest A., Moellering R.J., Elipopoulos G. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 2004, 42:2398-3402.
31. Schwaber M., Wright S., Carmeli Y., et al. Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg. Infect. Dis. 2003, 9:657-664.
32. Soriano A., Marco F., Martínez J., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2008, 46:193-200.
33. Stryjewski M., Szczech L., Benjamin D., et al. Use of vancomycin or first generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 2007, 44:190-196.
34. Yoon Y., Kim J., Park D., Sohn J., Kim M. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J. Antimicrob. Chemother. 2010, 65:1015-1018.